Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
Subscribe To Our Newsletter & Stay Updated
